The process of discovery and development of a molecule is complex, long and costly. Before making a decision on the offer that best meets your needs, we offer online scientific resources and our latest news to help you get to know us better. Our experts are also at your disposal to help and support you in your research and development program.
Filter by category
- All
- Blog
- Congress
- Scientific resource
- Webinar
- Poster
- Scientific publication
- Press release
- Press coverage
- News
Filter by category
Press release
08/02/2022
SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment
Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.
Scientific publication
06/01/2022
OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients
Early/ late resistance marker; Immunological profile; NGS; Non small-cell lung cancer; Pancreatic ductal adenocarcinoma; Triple negative breast or Luminal Breast Cancer.
Scientific publication
11/12/2021
Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections
SARS-CoV-2; antiviral drug combination; hepatitis C virus; hepatitis E virus; human immunodeficiency virus; influenza A virus; interferon-alpha.
Webinar
07/12/2021
Preclinical Models for Microbiome Research in Oncology and Inflammatory Diseases
Learn how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.
Webinar
16/11/2021
[EN] How Rodent and NHP Models Support COVID-19 Treatment Development
Learn how to select the most appropriate COVID-19 animal model for preclinical studies in this webinar
Webinar
05/11/2021
[EN] Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program
Learn how the DRIVE-MRT solution enables the rationalization, design & optimization of targeted & effective radiopharmaceuticals against specific cancers.
Press release
04/11/2021
ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease
Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia
News
28/10/2021
Oncodesign: EHDEN Certified SME
EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.
Press release
25/10/2021
Oncodesign has appointed Karine Lignel as Group Chief Development Officer
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Press release
21/10/2021
Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Webinar
20/10/2021
Pharmaco-imaging, COVID-19, Microbiome…
[Webinars] Radiopharmaceutics, COVID-19, Microbiome… join us this fall during a webinar
Poster
27/09/2021
Structure-Based Design of small macrocyclic CDK9 degraders as chemical biology tools and beyond
With small macrocyclic “probes” from our proprietary library in the low nanomolar range IC50, we turned our attention to CDK9 inhibitors with good selectivity profile against CDK1/2/5/7 as a starting point for building bifunctional small macrocyclic kinase degraders.